BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
FDA raised no concerns about Helix safety data, device performance or compatibility with general classes of agents.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCardia (BCDA) has completed a revised FDA De Novo pre-submission seeking clearance of its Helix catheter for delivery to the heart. The submission incorporates FDA advice on delivering therapeutic and diagnostic agents. At a May 2026 meeting, FDA agreed there were two pathways for marketing clearance and raised no concerns about safety data, device performance or compatibility with general classes of agents. FDA accepted the meeting minutes in August 2026.
The clinical experience includes 15 trials involving nearly 500 patients. This is a pre-submission, not marketing clearance. FDA targets an initial acceptance/refusal review within 15 calendar days and written feedback or a meeting within 70 calendar days. BioCardia sees potential for independent clearance to expand partnerships with developers of investigational cell, gene and protein therapeutics requiring targeted heart delivery.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointRevised De Novo pre-submission completed, incorporating FDA advice for Helix marketing clearance.
- Moderate pointFDA raised no concerns about safety data, device performance or compatibility with general classes of agents.
- Minor pointClinical experience spans 15 trials involving nearly 500 patients.
- Minor point. Forward-looking: it has not happened yet and may not happen.Independent clearance could expand partnerships with investigational therapy developers, BioCardia says.
Negative
- Moderate pointHelix marketing clearance remains pending; the completed step is a revised pre-submission.
Key Figures
- Initial review target
- 15 calendar days
- FDA acceptance/refusal review
- Feedback or meeting target
- 70 calendar days
- FDA written feedback or meeting
- Clinical trials
- 15 clinical trials
- Clinical data and safety profile cited for Helix
- Patients
- Nearly 500 patients
- Clinical data and safety profile cited for Helix
Previous Fda approval Reports
-
Filed an initial Helix pre-submission supported by safety and effectiveness data from 15 clinical trials.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
de novo regulatory
q-submission regulatory
non-inferiority medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised Pre-Submission to FDA Center for Devices and Radiological Health (CDRH) under its Q-Submission program for the approval of its Helix Catheter (“Helix”) for therapeutic and diagnostic agent delivery to the heart.
In May 2026, the Company and FDA met and reviewed our initial DeNovo pre-submission. FDA agreed that there are two pathways for Helix marketing clearance and raised no concerns regarding the Helix safety data, device performance, or compatibility with general classes of agents. In August 2026, the FDA confirmed and accepted the meeting minutes as summarized by BioCardia. The revised De Novo pre-submission for the Helix catheter incorporates the advice from FDA CDRH detailed in the minutes.
Should FDA enable Helix to be the first device of its kind cleared for market release by FDA, the extensive clinical data and safety profile from 15 clinical trials including nearly 500 patients presents opportunities for FDA to ensure that follow-on catheters demonstrate non-inferiority to the Helix catheter safety profile and clinical experience prior to their marketing clearance.
The FDA targets providing an initial acceptance/refusal review within 15 calendar days and aims to issue written feedback or hold a meeting within 70 calendar days.
An independent FDA clearance of Helix has the potential to expand BioCardia’s opportunities to partner with developers of investigational cell, gene and protein therapeutics requiring targeted delivery to the heart.
About BioCardia
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP™ autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information, visit www.biocardia.com.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements relating to the timing and potential outcome of BioCardia’s regulatory submissions for the Helix catheter.
These forward-looking statements are made as of the date of this press release. We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release.
Factors that could cause or contribute to such differences include, but are not limited to, the Company’s liquidity position and its ability to raise additional funds, as well as the Company’s ability to successfully progress its clinical trials and regulatory programs. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Media Contact:
Miranda Peto, Investor Relations
Email: mpeto@BioCardia.com
Phone: 650-226-0120
Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What regulatory step has BioCardia completed for the Helix catheter?
BioCardia has completed a revised De Novo pre-submission for Helix under FDA's Q-Submission program. It incorporates FDA advice concerning clearance for therapeutic and diagnostic agent delivery to the heart; it is not marketing clearance.
How soon does FDA target a response to BioCardia's Helix pre-submission?
FDA targets an initial acceptance/refusal review within 15 calendar days and aims to provide written feedback or hold a meeting within 70 calendar days. These are review targets, not a promised clearance date.
What could first-of-kind FDA clearance of BioCardia's Helix mean for follow-on catheters?
BioCardia says first-of-kind clearance could give FDA an opportunity to require follow-on catheters to demonstrate non-inferiority, meaning a safety profile no worse than Helix's, before marketing clearance. This is a conditional possibility, not an established FDA requirement.